This bill requires health insurance carriers in New Jersey to allow clinical laboratories and laboratory services providers to join their provider networks as preferred or contracting partners. The legislation mandates that insurance contracts must not deny these providers the right to participate under the same terms and conditions applied to other providers, provided they hold the necessary state or federal licenses and agree to the contract's terms. Additionally, the bill ensures that subscribers can choose their own laboratories without facing higher copayments or fees compared to other options, while also prohibiting insurers from restricting how providers charge for additional services like prescription counseling. These changes aim to increase competition and choice for patients by ensuring laboratories have equal access to insurance networks.
This bill prohibits health insurance carriers from denying coverage for nonopioid pain medications in favor of opioids or requiring patients to try opioids first. It requires insurers to treat FDA-approved nonopioid drugs equally to opioids in formularies, meaning coverage restrictions, prior authorization, and cost-sharing tiers must be no more restrictive for nonopioid drugs. The law applies to state health benefit plans, school employee health programs, and Medicaid for acute pain treatment. It takes effect January 1, 2026, directly affecting insurers and patients covered by these plans.
This bill would require New Jersey Medicaid to cover ovulation-enhancing drugs and related medical services without restrictions for beneficiaries experiencing infertility. It directly affects low-income New Jersey residents enrolled in Medicaid who seek infertility treatment. The key provision amends Medicaid law to explicitly include these services as a standard benefit, removing prior authorization requirements. This change would expand current coverage to ensure these treatments are accessible as routine care for eligible individuals.
This bill expands New Jersey's existing requirement for health insurance plans to cover prostate cancer screenings without any out-of-pocket costs. It specifically requires coverage for annual screenings - including digital rectal exams and PSA tests - for men aged 50 and older (asymptomatic) and men aged 40 and older with a family history of prostate cancer or other risk factors. The law applies to most health insurance plans, including high-deductible plans where permitted by federal law, and mandates coverage "to the same extent as for any other medical condition." It does not alter existing coverage for other preventive services but ensures no cost-sharing (like deductibles or copays) applies to these specific screenings.
This bill exempts drug manufacturers and distributors from New Jersey's pharmacy licensing requirements when distributing dialysate drugs and devices used for home dialysis treatment of end-stage renal disease patients. It directly affects dialysis manufacturers, distributors, and patients receiving home dialysis, allowing them to bypass standard pharmacy licensing rules under six specific conditions. Key provisions include requiring FDA approval, direct delivery only upon physician orders, original sealed packaging, and mandatory weekly quality checks by a consultant pharmacist. The law ensures these products are handled safely while streamlining access for patients needing home dialysis.
This bill updates regulations for health care facilities in New Jersey, specifically targeting narcotic and substance use disorder treatment centers. It increases the daily fines for operating these centers without approval or after a license is revoked, raising penalties from $25 to $12,500 for a first offense and from $50 to $25,000 for subsequent offenses. The legislation also grants the state commissioner expanded powers to conduct inspections, require detailed financial and quality reports, and appoint monitors for hospitals facing financial distress. Additionally, the bill allows owners and immediate family members to reside on the third floor of private long-term care facilities, overriding previous safety code restrictions.
This New Jersey bill creates a new crime called fertility fraud, which specifically targets licensed health care practitioners who knowingly use a patient's reproductive material without their written consent. Under the law, a practitioner commits this offense if they use their own sperm or eggs or the material of another person to cause a pregnancy without the patient's informed agreement. If convicted of this third-degree crime, the individual faces up to five years in prison, a fine of $15,000, and the mandatory permanent revocation of their medical license. Additionally, the legislation extends the statute of limitations for prosecuting this specific offense to 20 years from the date of the treatment or 10 years from when the victim discovers the fraud, whichever is later.
This bill requires state agencies to assess substance and alcohol use disorder treatment providers for conflicts of interest before approving state funding, licensure, or certification. Providers must submit detailed financial information, board member details, and lists of stakeholders with financial ties. If a conflict is identified that could affect care quality, the provider has 90 days to resolve it or risk losing funding/approval. After resolution, providers must undergo two additional conflict assessments within the next year. The law applies to all licensed or certifying state entities and defines conflicts as situations where outside financial interests might influence treatment decisions.
This bill requires New Jersey's Medicaid managed care organizations to automatically include lower-cost generic and biosimilar drugs on their formularies with better cost-sharing (like lower copays) when they are cheaper than the original brand drugs. It directly affects insurers managing Medicaid plans and their enrollees, ensuring patients pay less for equivalent treatments. Key provisions mandate that if a generic drug's price is lower than its reference brand at launch, insurers must list it with favorable cost-sharing and remove barriers like prior authorization. The bill does not force insurers to stop covering brand drugs but ensures cheaper alternatives are prioritized for cost savings. It applies only when cheaper options are available and respects medical appropriateness decisions by insurers.
This bill prohibits the $0.50 surcharge on rideshare trips that are designated for paratransit service, which includes transportation for people with disabilities and Medicaid non-emergency medical transport. It directly affects users of apps like Uber and Lyft who rely on these services for accessibility needs, ensuring they are not charged the extra fee required for regular prearranged rides. The legislation also clarifies that transportation network companies are not personally liable for these specific paratransit trips. By amending existing state laws, the bill removes the financial barrier for eligible riders while maintaining the surcharge for standard rides.
